Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,410,000 shares, an increase of 5.2% from the January 15th total of 1,340,000 shares. Based on an average trading volume of 419,500 shares, the short-interest ratio is currently 3.4 days. Approximately 4.6% of the company’s stock are sold short.

Institutional Investors Weigh In On iTeos Therapeutics

Large investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in iTeos Therapeutics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after acquiring an additional 690 shares during the last quarter. SG Americas Securities LLC acquired a new position in iTeos Therapeutics during the 3rd quarter worth $126,000. Creative Planning lifted its position in iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after acquiring an additional 1,196 shares during the last quarter. nVerses Capital LLC lifted its position in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Trading Up 0.5 %

Shares of NASDAQ:ITOS opened at $7.44 on Wednesday. The stock has a market capitalization of $271.78 million, a PE ratio of -2.36 and a beta of 1.38. iTeos Therapeutics has a 1 year low of $7.06 and a 1 year high of $18.75. The firm has a fifty day moving average price of $7.63 and a 200 day moving average price of $10.13.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ITOS. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of iTeos Therapeutics in a report on Thursday, January 16th. Wedbush restated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Friday, January 10th. Finally, Wells Fargo & Company decreased their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, December 19th.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.